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Abstract
Background: Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of
cancer deaths globally. However, there is overwhelming evidence that a large proportion of CRC cases and deaths
could be prevented by screening. Nevertheless, CRC screening programmes are offered in a minority of countries
only and often suffer from low adherence.
Discussion: Factors potentially accounting for hesitant implementation of and low adherence to CRC screening
may include a lower attention in the public and the media than for other cancers and the fairly long follow-up
time needed to fully disclose screening effects on CRC incidence and mortality. The latter results from the very slow
development of most CRCs through the adenoma-carcinoma sequence, and it challenges the predominant or even
exclusive reliance on evidence from randomized controlled trials in policy decisions on screening offers. Additional
key elements of future research should include (1) studies evaluating diagnostic performance of novel biomarkers
for non-invasive or minimally invasive CRC screening in true screening settings, (2) modelling studies evaluating
expected short- and long-term impact, effectiveness, and cost-effectiveness of various screening options, and
(3) timely and close monitoring of process quality and outcomes of existing and planned CRC screening programmes.
Most importantly, however, translation of the vast existing evidence on CRC screening into actual screening
programmes with the best possible levels of adherence needs to be fostered. This can be best achieved in
the context of organized programmes. Depending on available infrastructure and resources, epidemiological
patterns, population preferences, and costs, different screening offers might be preferred. According to current
evidence, colonoscopy, flexible sigmoidoscopy, and faecal occult blood tests (preferably faecal immunochemical tests)
are prime candidates for effective and cost-effective screening options, and microsimulation models should help to
tailor their implementation.
Summary: The strong evidence for the large potential of CRC screening in reducing the burden of CRC calls for
timely implementation of organized screening programmes where they are not in place yet, and for continuous
improvement of existing ones. This should be considered an obligation that is not to be postponed: the time
to act is now.
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Background
Colorectal cancer (CRC) is the third most common can-
cer and the fourth most common cause of cancer deaths
globally, accounting for approximately 1.4 million new
cases and 700,000 deaths every year [1]. Incidence is par-
ticularly high in developed countries; in Europe, CRC is
the second most common cancer. With approximately
450,000 new cases per year, case numbers are only
slightly lower than those of breast cancer patients. There
is meanwhile overwhelming evidence from both ran-
domized controlled trials (RCTs) and epidemiological
studies that a large proportion of CRC cases and deaths
could be prevented by screening with early detection
and removal of colorectal adenomas or early stage CRC
[2–4]. There is also overwhelming evidence that CRC
screening by either faecal occult blood test (FOBT), flex-
ible sigmoidoscopy, or colonoscopy is both effective and
cost-effective, even though uncertainty remains about
which of the screening options would be the most
cost-effective one [5]. Nevertheless, CRC screening
programmes continue to be offered in a minority of
countries only [6], and where they are offered there is
often much room for enhancing screening offers and
adherence. The aim of this article is to review poten-
tial reasons for this major translational gap, and to
discuss implications for further research and practice.
Discussion
Barriers hindering or delaying implementation of and
adherence to CRC screening
Several factors may have accounted for the reluctance to
implement (at the national, regional, or health system
level) and to adhere (at the individual level) to effective
CRC screening programmes. First, despite its frequency
and public health importance, CRC is a cancer that
might attract less attention than other cancers in the
public and the media. With a median age close to
70 years in many high income countries, it mainly
affects older adults, and the organ affected may be less
popular for media campaigns and other public relations
activities than other organs. Second, until recently, apart
from FOBT screening [2], evidence on the effectiveness
of CRC screening has not been available from long-term
RCTs [7–10], and no such evidence will be available for
screening colonoscopy, probably the most effective
screening examination, for many years to come. Third,
scientists are often very focused on dissemination of
their results in the scientific community, with less atten-
tion to disseminating practically relevant findings, such
as the available convincing evidence on effectiveness of
CRC screening, to the public and health policymakers or
to fostering translation into applied measures of preven-
tion. Fourth, politicians, healthcare stakeholders, and
healthcare providers may tend to focus on measures that
pay off in the short run, whereas most of the major ben-
efits of CRC screening in terms of prevented CRC cases
and deaths and of monetary savings from prevented
treatment costs are to be expected in the long run only.
Finally, necessary resources and infrastructure, e.g. for
high quality colonoscopy and for monitoring of
programme performance, continue to be limited in
many countries.
Specific chances and challenges resulting from the
natural history of CRC
A specific characteristic of CRC is the very slow devel-
opment of most cases through the adenoma-carcinoma
sequence, which often takes decades. For example, aver-
age annual transition rates from advanced adenomas to
preclinical CRC and from preclinical CRC to clinically
manifest CRC have been estimated in the order of <5 %
and 20 %, which translates to mean sojourn times of
advanced adenomas and preclinical CRC in the order
of >20 and 5 years, respectively [11, 12].
This slow development opens specific benefits such as
retardation of clinical manifestation of the disease into
older ages and a broad time window for detecting and
removing adenomas and preclinical CRC. On the other
hand, this characteristic also results in specific chal-
lenges: first, it will take several years if not decades until
the full effects of screening can be demonstrated by
RCTs or prospective cohort studies. For example, despite
RCTs on CRC screening by FOBT having been initiated
since the 1970s, full disclosure of screening effects is on-
going in the second decade of the 21st century [3, 13].
In the RCTs on screening by flexible sigmoidoscopy, the
reduction of CRC incidence and mortality only became
manifest after 10 or more years of follow-up (typically
15+ years after start of recruitment) [4], whereas an earl-
ier interim analysis of one of the trials conducted after
7 years of follow-up had essentially yielded negative
results [14].
Epidemiological studies and indirect evidence from
sigmoidoscopy trials suggest that still substantially larger
effects may be achieved by screening colonoscopy. How-
ever, the only RCT designed to assess reduction of CRC
incidence and mortality by screening colonoscopy com-
pleted recruitment only recently [15], and main results
after 15 years of follow-up will only become available
around 2030. In an era of widespread use of colonoscopy
for diagnostic purposes that takes place in many Western
countries and has similar protective effects as screening
colonoscopy (through detection and removal of adenomas
and preclinical CRC), substantial proportions of the con-
trol group of a colonoscopy screening trial can be ex-
pected to have a colonoscopy during follow-up. Such
“contamination” was already a major issue in the earlier
flexible sigmoidoscopy trials [9]. If not addressed in the
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analyses, major contamination in the control group will
lead to strong underestimation of effects in screening
trials [16]. Thus, while the principle effectiveness of
screening colonoscopy in reducing CRC mortality is ex-
tremely likely to be formally established by RCT evidence,
the estimated magnitude of the risk reduction will be at
least difficult to interpret and to generalize. Furthermore,
novel biomarker tests, endoscopic technology, and train-
ing are developing rapidly. Hence, RCT results of screen-
ing colonoscopy that pertain to colonoscopy technology
and training standards in 2010 will be highly interesting
but might be dispensable when main results will become
available around 2030.
Likewise, since initiation of the large FOBT trials,
which used guaiac-based FOBTs (gFOBTs), substantially
improved FOBTs have been developed. In particular,
fecal immunochemical tests (FITs) have been shown to
achieve substantially higher sensitivity at comparable
specificity for detecting colorectal adenomas and pre-
clinical CRC [17, 18]. Under these circumstances, de
novo initiation of RCTs demonstrating effectiveness or
superiority of FITs and other novel biomarker tests in
CRC screening that would take decades to complete
would not be a reasonable option.
Implications for research and practice
Notwithstanding the undoubted importance of RCTs
in demonstrating the principle effectiveness of medical
interventions in general and screening in particular,
the examples given above challenge the predominant
or even exclusive reliance on evidence from RCTs as a
basis for further progress in CRC screening. A comple-
mentary differentiated research agenda is required
that should include, as a guideline, the following key
elements:
 Studies evaluating the diagnostic performance of novel
biomarkers for non-invasive or minimally invasive
early detection of colorectal adenomas and preclinical
CRC, such as blood-, stool-, or urine-based biomarkers.
Ideally, such studies should be conducted in a true
screening setting among the target population of CRC
screening, and include as reference a diagnostic gold
standard and established non-invasive tests, such as
gFOBT and FIT, for comparison. Examples include
studies conducted among participants of screening
colonoscopy with biospecimen collection prior to
colonoscopy (e.g. [19, 20]).
 Modelling studies evaluating the expected short- and
long-term impact, effectiveness, and cost-effectiveness of
various screening options in specific target populations
for screening. Microsimulation models based on the
natural history of CRC development are a particularly
useful approach in this context [21, 22]. Apart from
modelling overall effectiveness and cost-effectiveness
of various screening methods, such approaches allow
for comparative evaluation of specific design options
of screening programmes, such as the start and end of
screening offers at various ages, various screening
intervals and follow-up schemes for surveillance
after detection of colorectal adenomas, or various
risk-adapted screening strategies based on a priori risk
stratification. In an era of rapidly increasing cancer
treatment costs, demonstration of cost-effectiveness
or even cost-savings of CRC screening strategies could
be particularly helpful for closing the translational gap
between scientific evidence and practice of CRC
screening [5].
 Timely and close monitoring of process quality
and outcomes of existing and newly introduced
CRC screening programmes. Guidelines for quality
assurance have been worked out in great detail
[23]. Key components include monitoring of
adherence to screening and surveillance offers,
positivity rates, and diagnostic performance of
screening tests, follow-up, and management of
positive results, stage-specific detection rates, and
outcomes of colorectal adenomas and preclinical
CRC, but also potential complications associated
with screening-induced diagnostic measures such
as colonoscopy (e.g. [24–26]).
 Timely and close monitoring of sex- and age-
specific CRC incidence and mortality in the target
population of screening based on data from
population-based cancer registries and mortality
statistics (e.g. [27, 28]). Both time trend analyses
assessing trends prior to and after implementation
of screening programmes in specific populations
as well as comparative analyses of CRC incidence
and mortality between populations with differential
screening coverage are of particular interest in this
context, along with studies with direct linkage of
screening and cancer registries [29].
Most importantly, however, it is time to foster transla-
tion of the already available overwhelming evidence on
the large potential of CRC screening into practice. This
not only applies to the large number of high incidence
countries where still no CRC screening programme is in
place and introduction of CRC screening should have a
high public health priority. There is also large potential
to substantially increase the impact of CRC screening
and further substantially reduce the burden of CRC inci-
dence and mortality by enhancing adherence to screen-
ing offers. For example, model calculations have shown
that most of the current CRC deaths in the United
States are attributable to non-screening [30], despite
substantially higher screening (especially endoscopic
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screening) coverage than in other countries. It has fur-
thermore been estimated that increasing screening rates
in the United States from approximately 58 % in 2013 to
80 % in 2018 would result in a reduction of CRC inci-
dence and mortality by 22 % and 30 %, respectively,
from 2013 to 2030. These reductions would amount to a
total of 277,000 averted new cancers and 203,000 averted
CRC deaths from 2013 through 2030 [31]. Even substan-
tially larger effects could be achieved in countries with
much lower adherence rates, such as Germany, where
screening colonoscopy has been offered since the end of
2002. Although this offer was used by only 20–25 % of
those eligible within the initial 10 years after its intro-
duction, it was estimated to have prevented approxi-
mately 180,000 new cases of CRC in the long run [32].
Experience from various countries shows that high ad-
herence rates can be best achieved by offer of screening
in the context of organized screening programmes with
personal invitation, follow-up of invitees, and compre-
hensive concepts for quality assurance and programme
evaluation.
Depending on availability of health care infrastructure
and resources, epidemiological patterns, population pref-
erences, and costs, different screening options might be
preferred and offered in various countries. According to
evidence available to date, colonoscopy, flexible sigmoid-
oscopy, and FOBTs would be prime candidates for ef-
fective and cost-effective screening options which might
be offered as alternative or complementary screening of-
fers, notwithstanding the lack of RCT results for colon-
oscopy which will not be available for many years.
Regarding FOBTs, there is convincing evidence that
quality-assured use of FIT should be preferred over the
use of gFOBT [33], despite restriction of direct evidence
from RCTs for the latter. Apart from the choice of
specific screening offers, numerous decisions have to
be made, such as definition of the target population
for screening, screening and surveillance intervals,
and potential risk stratification in screening. Microsi-
mulation models appear to be the most promising ap-
proach to make such decisions as evidence-based as
possible and should be more widely used in this con-
text. They might also be particularly helpful to the
timely evaluation of the potential role of emerging
novel non- or minimally-invasive screening tests or
imaging technologies that might enhance the spectrum
of effective and cost-effective screening options in the
future.
Summary
The available evidence strongly suggests that there is a
large but widely underused potential for CRC screen-
ing in reducing the burden of CRC incidence and mor-
tality. It calls for timely implementation of organized
screening programmes where they are not in place yet,
and for continuous improvement of existing offers
where such programmes exist. This should be consid-
ered an obligation that is not to be postponed: the
time to act is now.
Abbreviations
CRC: Colorectal cancer; FIT: Faecal immunochemical test; FOBT: Faecal occult
blood test; gFOBT: Guaiac-based faecal occult blood test; RCT: Randomized
controlled trial.
Competing interests
Research on colorectal cancer screening conducted in the Division of
Clinical Epidemiology and Aging Research at the German Cancer Institute
has been partly funded by industrial research grants from Eiken Chemicals,
Epigenomics, Roche Diagnostics and Applied Proteomics to the German
Cancer Research Center. Hermann Brenner has applied for a patent “Biomarker
panel for diagnosing cancer” (Application Number: EP 15161465.8 Priority
Date: 27.03.2015).
Authors’ contributions
All authors reviewed the literature. HB drafted and finalized the manuscript.
CS and MH reviewed the draft and made constructive suggestions for its
finalization. All authors read and approved the final manuscript.
Acknowledgements
The work of Hermann Brenner and Michael Hoffmeister on colorectal
cancer screening was funded in part by grants from the German Federal
Ministry of Education and Research, the German Research Council (Deutsche
Forschungsgemeinschaft), the German Cancer Aid (Deutsche Krebshilfe), and
the Central Institute for Ambulatory Care in Germany. The sponsors had no role
in design, in the collection, analysis, and interpretation of data; in the writing of
the manuscript; and in the decision to submit the manuscript for publication.
Author details
1Division of Clinical Epidemiology and Aging Research, German Cancer
Research Center (DKFZ), INF 581, 69120 Heidelberg, Germany. 2Division of
Preventive Oncology, German Cancer Research Center (DKFZ) and National
Center for Tumor Diseases (NCT), INF 460, 69120 Heidelberg, Germany.
3German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
INF 280, 69120 Heidelberg, Germany. 4Institute of Medical Biometry and
Informatics, University of Heidelberg, INF 305, 69120 Heidelberg, Germany.
Received: 28 August 2015 Accepted: 25 September 2015
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11. Lyon, France: International Agency for Research on
Cancer; 2013. http://globocan.iarc.fr. Accessed 17 August 2015.
2. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic
review of colorectal cancer screening using the fecal occult blood test
(hemoccult): an update. Am J Gastroenterol. 2008;103:1541–9.
3. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al.
Long-term mortality after screening for colorectal cancer. N Engl J Med.
2013;369:1106–14.
4. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and
screening colonoscopy on colorectal cancer incidence and mortality:
systematic review and meta-analysis of randomised controlled trials and
observational studies. BMJ. 2014;348:g2467. doi:10.1136/bmj.g2467.
5. Lansdorp-Vogelaar I, Knudsen A, Brenner H. Cost-effectiveness of colorectal
cancer screening. Epidemiol Rev. 2011;33:88–100.
6. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al.
Colorectal cancer screening: a global overview of existing programmes. Gut.
2015;64:1637–49. doi:10.1136/gutjnl-2014-309086.
7. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA,
et al. Once-only flexible sigmoidoscopy screening in prevention of
colorectal cancer: a multicentre randomised controlled trial. Lancet.
2010;375:1624–33.
Brenner et al. BMC Medicine  (2015) 13:262 Page 4 of 5
8. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only
sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian
Randomized Controlled Trial – SCORE. J Natl Cancer Inst. 2011;103:1310–22.
9. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al.
Colorectal-cancer incidence and mortality with screening flexible
sigmoidoscopy. N Engl J Med. 2012;366:2345–57.
10. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect
of flexible sigmoidoscopy screening on colorectal cancer incidence and
mortality. JAMA. 2014;312:606–15.
11. Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal
adenomas: Birth cohort analysis among 3.6 million participants of screening
colonoscopy. Cancer Epidemiol Biomarkers Prev. 2013;22:1043–51.
12. Brenner H, Altenhofen L, Katalinic A, Lansdorp-Vogelaar I, Hoffmeister M.
Sojourn time of preclinical colorectal cancer by sex and age: estimates from
the German national screening colonoscopy database. Am J Epidemiol.
2011;174:1140–6.
13. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD.
Nottingham trial of faecal occult blood testing for colorectal cancer: a
20-year follow-up. Gut. 2012;61:1036–40.
14. Hoff G, Grotmol T, Skovlund E, Bretthauer M, for the Norwegian Colorectal
Cancer Prevention Study Group. Risk of colorectal cancer seven years after
flexible sigmoidoscopy screening: randomised controlled trial. BMJ.
2009;338:b1846.
15. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami H-O, van
Ballegooijen M, et al. The NordICC Study: Rationale and design of a
randomized trial on colonoscopy screening for colorectal cancer.
Endoscopy. 2012;44:695–702.
16. Brenner H, Stock C, Hoffmeister M. In the era of widespread endoscopy use
randomized trials may strongly underestimate effects of colorectal cancer
screening. J Clin Epidemiol. 2013;66:1144–50.
17. Brenner H, Tao S. Superior diagnostic performance of fecal immunochemical
tests for hemoglobin in a head-to-head comparison with guaiac based fecal
occult blood test among 2235 participants of screening colonoscopy. Eur J
Cancer. 2013;49:3049–54.
18. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal
immunochemical tests for colorectal cancer: systematic review and
meta-analysis. Ann Intern Med. 2014;160:171.
19. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al.
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med.
2014;370:1287–97.
20. Chen H, Zucknick M, Werner S, Brenner H. Head-to head comparison and
evaluation of 92 plasma protein biomarkers for early detection of colorectal
cancer in a true screening setting. Clin Cancer Res. 2015;21:3318–26.
21. Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF,
et al. Models in the development of clinical practice guidelines. Ann Intern
Med. 2014;161:812–8.
22. van Hees F, Zauber AG, van Veldhuizen H, Heijnen ML, Penning C,
de Koning HJ, et al. The value of models in informing resource
allocation in colorectal cancer screening: the case of the Netherlands.
Gut. 2015. doi:10.1136/gutjnl-2015-309316. Ahead of print.
23. European Colorectal Cancer Screening Guidelines Working Group. European
guidelines for quality assurance in colorectal cancer screening and
diagnosis: overview and introduction to the full supplement publication.
Endoscopy. 2013;45:51–9.
24. Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C.
Colorectal cancer screening uptake over three biennial invitation rounds in
the English bowel cancer screening programme. Gut. 2015;64:282–91.
25. Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E,
Elferink MA, et al. Participation, yield, and interval carcinomas in three
rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol.
2015;39:388–93.
26. Pox CP, Altenhofen L, Brenner H, Theilmeier A, von Stillfried D, Schmiegel W.
Efficacy of a nationwide screening colonoscopy program for colorectal cancer.
Gastroenterology. 2012;142:1460–7.
27. McClements PL, Madurasinghe V, Thomson CS, Fraser CG, Carey FA,
Steele RJ, et al. Impact of the UK colorectal cancer screening pilot
studies on incidence, stage distribution and mortality trends. Cancer
Epidemiol. 2012;36:e232–42.
28. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact
on colorectal cancer mortality of screening programmes based on faecal
immunochemical test. Gut. 2015;64:784–90.
29. Anttila A, Lönnberg S, Ponti A, Suonio E, Villain P, Coebergh JW, et al.
Towards better implementation of cancer screening in Europe through
improved monitoring and evaluation and greater engagement of cancer
registries. Eur J Cancer. 2015;51:241–51.
30. Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR,
Quinn VP, et al. Colorectal cancer deaths attributable to nonuse of
screening in the United States. Ann Epidemiol. 2015;25:209–13.
31. Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, et al.
Public health impact of achieving 80 % colorectal cancer screening rates in
the United States. Cancer. 2015. doi:10.1002/cncr.29336. Ahead of print.
32. Brenner H, Altenhofen L, Stock C, Hoffmeister M. Prevention, early detection,
and overdiagnosis of colorectal cancer within 10 years of screening
colonoscopy in Germany. Clin Gastroenterol Hepatol. 2015;13:717–23.
33. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical
tests versus guaiac faecal occult blood tests: what clinicians and
colorectal cancer screening programme organisers need to know. Gut.
2015;64:1327–37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brenner et al. BMC Medicine  (2015) 13:262 Page 5 of 5
